Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 19/20 | 0.51 |
| ▸ | CDK2 | P24941 | 6/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
| ▸ | CCNH | P51946 | 1/20 | 0.38 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.38 |
| ▸ | INSR | P06213 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3551373 | 0.93 | IGF1R (0.45) | IGF1RCDK2KCNH2CDK1CCNB1 | |
| SCHEMBL3555012 | 0.91 | IGF1R (0.44) | IGF1RCDK2CDK1CCNB1FLT3 | |
| SCHEMBL3552586 | 0.91 | IGF1R (0.44) | IGF1RCDK2CDK1CCNB1FLT3 | |
| SCHEMBL3554792 | 0.90 | IGF1R (0.44) | IGF1RCDK2CDK1CCNB1FLT3 | |
| SCHEMBL3555421 | 0.90 | IGF1R (0.48) | IGF1RCDK2KCNH2CDK1CCNB1 | |
| SCHEMBL3556362 | 0.90 | IGF1R (0.45) | IGF1RCDK2CDK1CCNB1FLT3 | |
| SCHEMBL3559556 | 0.89 | IGF1R (0.43) | IGF1RCDK2CDK1CCNB1FLT3 | |
| SCHEMBL3557009 | 0.88 | IGF1R (0.43) | IGF1RCDK2CDK1CCNB1FLT3 | |
| SCHEMBL3557779 | 0.86 | IGF1R (0.45) | IGF1RCDK2KCNH2CDK1CCNB1 | |
| SCHEMBL3554402 | 0.83 | IGF1R (0.48) | IGF1RCDK2KCNH2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718801-B2 | Substituted imidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1790650-A1 | NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | PLK1, CDK1, CDK11A | IGF1R 101/4885CDK2 72/4885KCNH2 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.